Ab Science

Clinical‑stage pharmaceutical AB Science focuses on masitinib, a Phase‑III kinase inhibitor for ALS, MS, Alzheimer and mastocytosis, with AB8939 in Phase‑I AML trials. Masivet sold in Europe, HQ Paris.

Headquarters: France (FRA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 36
HQ: Paris

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
AB	Ab Science Cap: 0.1B	EQUITY	PAR	EUR	FR0010557264	Active	📈